This year has been quite a doozie for marijuana stocks. 2020 started out looking like it would be a promising time for the cannabis market, but then the coronavirus quickly took its toll. Now, we are in the midst of a pandemic, and we continue to see trading with cannabis stocks done off of fear. This fear-based trading is the main reason behind the large volatility that we have seen in the cannabis market for most of 2020.

A merger of cannabis giants Aphria and Tilray is poised to create a massive shift in the marijuana industry. The two companies announced the plans Dec. 16, with hopes of wrapping the process up in the second quarter of 2021. 

Aphria and Tilray announced they will be merging to create a leading global company accrediting cannabis communities worldwide. It is expected to generate around $100 million pre-tax annually based on the share price of Aphria and Tilray as of Dec. 15.

Battling cancer is one of the toughest things a person can do. Recent research says many of those afflicted may uses cannabis to treat their symptoms.

As of right now, there is no definitive cure for cancer, and that is beyond unfortunate. Hopefully, treatments will soon be developed that consistently cure all forms of the disease.

Until that happens, suffering patients will need to treat their cancer via whatever means their doctor deems appropriate and effective.

Medical cannabis is one treatment more and more patients are turning to.

Holiday festivities have been curtailed by the global resurgence of the COVID-19 pandemic, and its unprecedented social and economic effects. During this turbulent season, cannabis companies all over North America continue to do what they can to support local charities and populations in need.

So, let this 2020 holiday season be lit with the warmth of giving. Here’s a short list of holiday fundraising activities led by cannabis industry members, bringing happiness and help to so many for the season as we all look forward to a new year in 2021:

Canopy Rivers Inc. has entered into an agreement with Canopy Growth Corporation in which Rivers will transfer three portfolio assets to Canopy Growth in exchange for $115 million in cash and 3,750,000 common shares of Canopy Growth and the cancellation of all 36,468,318 Multiple Voting Shares and the 15,223,938 Subordinate Voting Shares of Rivers held by Canopy Growth.

A researcher has found that one-third of Canadian cancer patients use marijuana, according to a study released earlier this month. A report on the research, “Cannabis use among Canadian adults with cancer (2007-2016): results from a national survey,” was published online by the journal Expert Reviews in Pharmacoeconomics & Outcome Research. 

Following the results of the 2020 presidential election, cannabis advocates across the nation breathed a sigh of relief; for the first time in our history, cannabis decriminalization was being supported by the party in office. Since 2012, 15 states and Washington, DC, have legalized cannabis for adults over the age of 21. And 36 states have legalized medical cannabis — meaning that a majority of Americans now have some form of access to cannabis, whether medically or recreationally. On December 4th, the House passed the Marijuana Opportunity, Reinvestment, and Expungement (MORE) Act, a historic bill which will remove cannabis from the Controlled Substances Act and serves as the first step in ultimately deciding the fate of federal decriminalization in the United States. 

(Reuters) - Canadian health regulator on Thursday raised concerns about the large quantity of medical marijuana people were growing at home, after its data showed a significant jump in daily average production permitted by health care practitioners.

While the practitioners can allow registered patients to grow limited amount at home for personal use, the regulator’s findings show that such authorizations rose to a staggering 36.2 grams by the end of March, compared with 25.2 grams in October 2018.

Meanwhile, average purchases by registered patients, who can buy pot from licensed producers and federal medical sellers, have stayed as low as 2 to 2.1 grams every month, data showed.